Survival of the Fittest: Darwinian Selection Underpins Chemotherapy Resistance in AML

Laura MacPherson; Mark A Dawson

doi:10.1016/j.stem.2017.08.004

Survival of the Fittest: Darwinian Selection Underpins Chemotherapy Resistance in AML

Cell Stem Cell. 2017 Sep 7;21(3):291-292. doi: 10.1016/j.stem.2017.08.004.

Authors

Laura MacPherson¹, Mark A Dawson²

Affiliations

¹ Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, VIC, Australia.
² Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, VIC, Australia; Centre for Cancer Research, University of Melbourne, Melbourne, VIC, Australia; Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. Electronic address: mark.dawson@petermac.org.

PMID: 28886361
DOI: 10.1016/j.stem.2017.08.004

Abstract

Intratumor heterogeneity driving therapeutic resistance is a major challenge in cancer management. Recently in Nature, Shlush et al. (2017) provide a tour de force of genomics coupled to functional assays to demonstrate that resistance emerges from a pre-existing subpopulation of acute myeloid leukemia (AML) cells with a stem cell transcription program.

Publication types

Comment

MeSH terms

Genomics
Humans
Leukemia, Myeloid, Acute*
Recurrence
Stem Cells